Craig Hallum Raises Xeris Biopharma (NASDAQ:XERS) Price Target to $6.50

Xeris Biopharma (NASDAQ:XERS) had its target price increased by analysts at Craig Hallum from $5.00 to $6.50 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Craig Hallum’s price objective points to a potential upside of 53.30% from the company’s current price.

A number of other equities analysts have also commented on the stock. Piper Sandler restated a “neutral” rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a report on Friday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.90.

Xeris Biopharma Stock Performance

Shares of NASDAQ XERS opened at $4.24 on Friday. Xeris Biopharma has a 52-week low of $1.69 and a 52-week high of $4.50. The business has a fifty day moving average of $3.57 and a two-hundred day moving average of $3.26. The stock has a market cap of $632.10 million, a PE ratio of -9.42 and a beta of 2.32.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC acquired a new stake in Xeris Biopharma in the fourth quarter worth about $34,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Xeris Biopharma in the 3rd quarter valued at about $35,000. R Squared Ltd acquired a new stake in shares of Xeris Biopharma during the 4th quarter worth approximately $42,000. Quantbot Technologies LP bought a new stake in shares of Xeris Biopharma during the third quarter worth approximately $44,000. Finally, Cibc World Markets Corp acquired a new position in Xeris Biopharma in the fourth quarter valued at approximately $44,000. 42.75% of the stock is owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.